• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Cannabidiol Could Alleviate Psychotic Symptoms in Schizophrenia

Cannabidiol Could Alleviate Psychotic Symptoms in Schizophrenia

November 1, 2017
Rehan Aziz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Leweke FM et al, Transl Psychiatry 2012;2:e94

Research has shown that heavy cannabis use is associated with new-onset psychosis, so a study exploring the drug’s use as a treatment for schizophrenia is surprising, to say the least. Recall that cannabis is composed of more than 100 compounds, and that delta-9-tetrahydrocannabinol (THC) is the most psychoactive one.

Cannabidiol, on the other hand, does not have the same psychoactive properties as THC or its potential to induce psychosis. However, cannabidiol does inhibit the breakdown of anandamide, an endogenous cannabinoid. In studies, the prevention of anandamide breakdown has improved psychotic symptoms. So it is thought, by inhibiting anandamide degradation, cannabidiol might act as an antipsychotic in patients with schizophrenia.

Leweke et al’s study, which took place in Germany, sought to test this claim by looking at 42 men and women ages 18–50, all hospitalized and suffering from acute exacerbations of schizophrenia. In a double-blinded fashion, subjects were randomly assigned to receive either cannabidiol (n = 21) or the second-generation antipsychotic amisulpride (n = 21), at doses up to 800 mg/day each, for 4 weeks. (Amisulpride is an atypical antipsychotic, not marketed in Canada or the US, that is associated with moderate amounts of extrapyramidal symptoms and prolactin elevation.) The main outcome measures were obtained at baseline, day 14, and day 28, and included serum anandamide and prolactin levels, a Positive and Negative Symptoms of Schizophrenia (PANSS) score, weight gain, and extrapyramidal movements.

Overall, patients treated with either agent showed significant clinical improvement and reduction in schizophrenia symptoms. Patients assigned to cannabidiol showed a total PANSS reduction of 30.5, and those on amisulpride showed a reduction of 30.1. There was no significant difference between the two treatments. Still, compared with amisulpride, there were significantly fewer extrapyramidal symptoms with cannabidiol, less weight gain, and lower prolactin increase. Serum anandamide levels were higher in patients who received cannabidiol, and were associated with reduced psychotic symptoms.

CATR’s Take
The results of this small, single-site study suggest cannabidiol may be as effective in treating psychosis as standard antipsychotics and may have a superior side effect profile. If larger studies can reproduce these findings, cannabinoid may represent a breakthrough in schizophrenia treatment.
Addiction Treatment
KEYWORDS antipsychotics research-update
Rehan Aziz, MD.

Mood Stabilizers for Bipolar Disorder in Older Adults: Special Considerations

More from this author
www.thecarlatreport.com
Issue Date: November 1, 2017
SUBSCRIBE NOW
Table Of Contents
Substance Use in Pregnancy: What to Tell Patients
Pregnancy and Substance Use Disorders
Can Just 11 Minutes of Mindfulness Training Reduce Alcohol Consumption?
Cannabidiol Could Alleviate Psychotic Symptoms in Schizophrenia
CME Post-Test - Pregnancy and Addiction, CATR, November/December 2017
New Editor-in-Chief!
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.